Previous 10 | Next 10 |
2024-04-04 16:57:58 ET Summary Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to Gilead, but I wouldn't be surprised if Werewolf T...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
NORTHAMPTON, MA / ACCESSWIRE / April 2, 2024 / Women represent more than half of Gilead's workforce, and our weighted salary ratio for women to men globally in 2023 was 99.93:100. We'll continue our efforts to champion an environment of equality and inclusion for all. Gilead Sciences Gilead ...
2024-04-02 08:20:53 ET More on Nurix Therapeutics Nurix Therapeutics: A Unique Approach To BTK Targeting Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now FDA lifts partial hold on Nurix Phase 1 study for NX-2127 Nurix g...
2024-04-02 02:17:00 ET Summary Gilead Sciences is a potential buy due to its attractive valuation, potential for capital gains, and transformative acquisitions. Gilead shares have pulled back from recent highs, offering an opportunity to buy a leading company in the sector with a ...
2024-03-28 11:10:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xilio Therapeutics (NASDAQ: XLO ) stock is rocketing higher on Thursday after the clinical-stage biotechnology company signed an exclusive license agreement with Gilead Scienc...
2024-03-28 11:04:59 ET More on Gilead Sciences Gilead Sciences Finally Starts Succeeding Gilead Sciences: Realizing Financial Projections Is Key Gilead Sciences, Inc. (GILD) Barclays 26th Annual Global Healthcare Conference (Transcript) Xilio stock jumps on G...
2024-03-28 09:20:29 ET DENVER, Colo., Mar 28, 2024 ( 247marketnews.com )- This morning’s notable listings with recent news include Treasure & Shipwreck Recovery (OTCPK: BLIS ), Akebia Therapeutics, Inc. (NASDAQ: AKBA ), Avalo Therapeutics, Inc. (NASDAQ: AV...
– Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new ...
2024-03-28 08:23:29 ET Gilead Sciences ( NASDAQ: GILD ) has signed an exclusive license deal to develop and commercialize Xilio Therapeutics’ ( NASDAQ: XLO ) XTX301, an investigational tumor-activated IL-12 program with potential to treat a broad range of cancers....
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...